$DNLI
Denali Therapeutics Inc.

2024 Q3 Form 10-Q Financial Statement

#000171489924000169 Filed on August 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.95M $25.19M
YoY Change -1.39% -3.55%
% of Gross Profit
Research & Development $98.24M $91.40M
YoY Change 9.47% -6.28%
% of Gross Profit
Depreciation & Amortization $2.269M $1.942M
YoY Change 3.14% -15.01%
% of Gross Profit
Operating Expenses $123.2M $116.6M
YoY Change 7.06% -5.7%
Operating Profit -$123.2M -$116.6M
YoY Change 8.25% -168.39%
Interest Expense $16.00M $17.57M
YoY Change 11.08% 36.18%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$107.2M -$99.03M
YoY Change 7.84% -154.0%
Income Tax
% Of Pretax Income
Net Earnings -$107.2M -$99.03M
YoY Change 7.89% -154.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.63 -$0.59
Diluted Earnings Per Share -$0.63 -$0.59
COMMON SHARES
Basic Shares Outstanding 143.2M shares 142.6M shares
Diluted Shares Outstanding 169.5M shares 168.8M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $836.6M $896.0M
YoY Change -24.48% -24.76%
Cash & Equivalents $90.64M $74.68M
Short-Term Investments $745.9M $821.4M
Other Short-Term Assets $32.28M $32.34M
YoY Change -8.3% -2.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $868.8M $928.4M
YoY Change -23.98% -24.16%
LONG-TERM ASSETS
Property, Plant & Equipment $50.82M $48.08M
YoY Change 5.66% 20.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $445.5M $451.0M
YoY Change 5538.77%
Other Assets $26.49M $50.58M
YoY Change 137.83% 250.41%
Total Long-Term Assets $585.2M $574.2M
YoY Change 523.23% 603.03%
TOTAL ASSETS
Total Short-Term Assets $868.8M $928.4M
Total Long-Term Assets $585.2M $574.2M
Total Assets $1.454B $1.503B
YoY Change 17.56% 15.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.594M $13.94M
YoY Change 699.5% 63.57%
Accrued Expenses $4.829M $6.013M
YoY Change -91.9% -88.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $87.09M $74.53M
YoY Change 22.36% 7.46%
LONG-TERM LIABILITIES
Long-Term Debt $5.631M $0.00
YoY Change
Other Long-Term Liabilities $42.79M $40.98M
YoY Change 11191.29% 10712.93%
Total Long-Term Liabilities $48.43M $40.98M
YoY Change 12677.04% 10712.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $87.09M $74.53M
Total Long-Term Liabilities $48.43M $40.98M
Total Liabilities $135.5M $115.5M
YoY Change 14.41% -2.86%
SHAREHOLDERS EQUITY
Retained Earnings -$1.424B -$1.317B
YoY Change 42.89% 46.76%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.318B $1.387B
YoY Change
Total Liabilities & Shareholders Equity $1.454B $1.503B
YoY Change 17.56% 15.07%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$107.2M -$99.03M
YoY Change 7.89% -154.0%
Depreciation, Depletion And Amortization $2.269M $1.942M
YoY Change 3.14% -15.01%
Cash From Operating Activities -$59.14M -$91.22M
YoY Change -32.26% -19.39%
INVESTING ACTIVITIES
Capital Expenditures $3.884M $4.786M
YoY Change 84.95% -18.19%
Acquisitions
YoY Change
Other Investing Activities $97.54M $103.4M
YoY Change -5.3% -40.57%
Cash From Investing Activities $93.65M $98.57M
YoY Change -7.18% -41.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -18.56M 6.756M
YoY Change -842.36% -25.09%
NET CHANGE
Cash From Operating Activities -59.14M -91.22M
Cash From Investing Activities 93.65M 98.57M
Cash From Financing Activities -18.56M 6.756M
Net Change In Cash 15.96M 14.11M
YoY Change -0.89% -77.93%
FREE CASH FLOW
Cash From Operating Activities -$59.14M -$91.22M
Capital Expenditures $3.884M $4.786M
Free Cash Flow -$63.02M -$96.01M
YoY Change -29.5% -19.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.30
CY2024Q2 dnli Accrued Clinical And Other Research And Development Costs Current
AccruedClinicalAndOtherResearchAndDevelopmentCostsCurrent
19915000 usd
CY2024Q2 dnli Other Accrued Manufacturing Costs Current
OtherAccruedManufacturingCostsCurrent
7111000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
74533000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44981000 usd
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138385498 shares
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
329264000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
294123000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
226336000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
53260000 usd
us-gaap Operating Expenses
OperatingExpenses
279596000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-116593000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159117759 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q4 dnli Accrued Clinical And Other Research And Development Costs Current
AccruedClinicalAndOtherResearchAndDevelopmentCostsCurrent
19035000 usd
CY2023Q4 dnli Other Accrued Manufacturing Costs Current
OtherAccruedManufacturingCostsCurrent
15462000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
1076000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-3302000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.34
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168831329 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137047227 shares
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50578000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18143000 usd
CY2024Q2 us-gaap Assets
Assets
1502565000 usd
CY2023Q4 us-gaap Assets
Assets
1153917000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
13936000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9483000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6013000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000 usd
CY2024Q2 dnli Deferred Liability Capitalized Research And Development Costs
DeferredLiabilityCapitalizedResearchAndDevelopmentCosts
10232000 usd
CY2023Q4 dnli Deferred Liability Capitalized Research And Development Costs
DeferredLiabilityCapitalizedResearchAndDevelopmentCosts
0 usd
CY2024Q2 us-gaap Liabilities
Liabilities
115514000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
122963000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1711000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2704992000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1116211000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1387051000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1030954000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1502565000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1153917000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159117759 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136787321 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168831329 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
140930625 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159117759 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1030954000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
480000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
499253000 usd
dnli Stock Issued During Period Value Equity Incentive Plan
StockIssuedDuringPeriodValueEquityIncentivePlan
7778000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
53196000 usd
us-gaap Net Income Loss
NetIncomeLoss
-200828000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3302000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1387051000 usd
CY2024Q2 dnli Stock Issued During Period Value Equity Incentive Plan
StockIssuedDuringPeriodValueEquityIncentivePlan
6755000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25210000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-99026000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1363000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1387051000 usd
dnli Stock Issued During Period Value Equity Incentive Plan
StockIssuedDuringPeriodValueEquityIncentivePlan
10623000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
54725000 usd
us-gaap Net Income Loss
NetIncomeLoss
73602000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5445000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1186825000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
77982000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40981000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
143123582 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
143123582 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
138385498 shares
CY2024Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1757000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2144811000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2659000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
643000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1317039000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
294123000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91399000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97520000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
198415000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25194000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26120000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50430000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
116593000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
123640000 usd
us-gaap Operating Expenses
OperatingExpenses
248845000 usd
CY2024Q2 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
CY2023Q2 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14537000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
170483000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-234308000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
49668000 usd
CY2024Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
17567000 usd
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
12900000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
33480000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
23934000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-99026000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
183383000 usd
us-gaap Net Income Loss
NetIncomeLoss
-200828000 usd
us-gaap Net Income Loss
NetIncomeLoss
73602000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-1363000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
5445000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-100389000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
184459000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-204130000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
79047000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.54
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2023Q2 dnli Stock Issued During Period Value Equity Incentive Plan
StockIssuedDuringPeriodValueEquityIncentivePlan
9019000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26641000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
183383000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1076000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1186825000 usd
us-gaap Net Income Loss
NetIncomeLoss
-200828000 usd
us-gaap Net Income Loss
NetIncomeLoss
73602000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4104000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12332000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
52940000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
54654000 usd
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
20574000 usd
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
19386000 usd
dnli Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
1976000 usd
dnli Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
1805000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
14537000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20336000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1823000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4523000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8472000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-8156000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-12399000 usd
dnli Increase Decrease In Contract With Customer Liability Related Parties
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties
0 usd
dnli Increase Decrease In Contract With Customer Liability Related Parties
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties
-289264000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-204840000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-171971000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
955802000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
901841000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6936000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8636000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
608120000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
985829000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-354618000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
75352000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
480000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
499253000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7778000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
10623000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
507031000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10623000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52427000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-85996000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128681000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
219544000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76254000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133548000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000 usd
us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
15000000 usd
us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
228000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
575000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of June 30, 2024 and December 31, 2023, the Company had no off-balance sheet concentrations of credit risk. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other clinical-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Further, the company is also subject to broad market risks and uncertainties resulting from recent events, such as bank failures or instability in the financial services sector, global pandemics, war and armed conflicts, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.</span></div>
CY2023Q4 dnli Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk Amount
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount
0 usd
CY2024Q2 dnli Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk Amount
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount
0 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1600000 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1325665000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1274667000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2315000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1272359000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
906410000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
998000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
907405000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
dnli Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
2300000 usd
CY2024Q2 dnli Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
2300000 usd
CY2024Q2 dnli Deferred Liability Capitalized Research And Development Costs
DeferredLiabilityCapitalizedResearchAndDevelopmentCosts
10200000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
294123000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
329264000 usd
CY2024Q2 dnli Research And Development Expense Offset From Cost Reimbursement
ResearchAndDevelopmentExpenseOffsetFromCostReimbursement
3087000 usd
CY2023Q2 dnli Research And Development Expense Offset From Cost Reimbursement
ResearchAndDevelopmentExpenseOffsetFromCostReimbursement
3507000 usd
dnli Research And Development Expense Offset From Cost Reimbursement
ResearchAndDevelopmentExpenseOffsetFromCostReimbursement
6163000 usd
dnli Research And Development Expense Offset From Cost Reimbursement
ResearchAndDevelopmentExpenseOffsetFromCostReimbursement
4522000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3100000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
6200000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3300000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
6200000 usd
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
2854000 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
2763000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
5647000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
5759000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5770000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11793000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12182000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12584000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13001000 usd
CY2024Q2 dnli Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
4381000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
59711000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10959000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
48752000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16490551 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4370561 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
20.25
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
453206 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1435314 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
30.95
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18972592 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.84
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
18162721 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.85
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11565306 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
27.31
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25100000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26570000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
52940000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
54654000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-99026000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
183383000 usd
us-gaap Net Income Loss
NetIncomeLoss
-200828000 usd
us-gaap Net Income Loss
NetIncomeLoss
73602000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
142785264 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
137047227 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
141515199 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
136787321 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168831329 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137047227 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159117759 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136787321 shares
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3883398 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3762905 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168831329 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
140930625 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
140550226 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23300000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11800000 shares
CY2024Q2 dnli Lessor Operating Sublease Rentable Area
LessorOperatingSubleaseRentableArea
12985 sqft
CY2024Q2 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P10M
CY2024Q2 dnli Lessor Operating Sublease Number Of Options To Extend
LessorOperatingSubleaseNumberOfOptionsToExtend
2 extension_option
CY2024Q2 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P6M
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001714899-24-000169-index-headers.html Edgar Link pending
0001714899-24-000169-index.html Edgar Link pending
0001714899-24-000169.txt Edgar Link pending
0001714899-24-000169-xbrl.zip Edgar Link pending
denali-biogensideletter.htm Edgar Link pending
dnli-20240630.htm Edgar Link pending
dnli-20240630.xsd Edgar Link pending
exhibit311q22024.htm Edgar Link pending
exhibit312q22024.htm Edgar Link pending
exhibit321q22024.htm Edgar Link pending
exhibit322q22024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
dnli-20240630_def.xml Edgar Link unprocessable
dnli-20240630_pre.xml Edgar Link unprocessable
dnli-20240630_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dnli-20240630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dnli-20240630_lab.xml Edgar Link unprocessable